SG11202104384PA - Substituted oxopyridine derivatives - Google Patents
Substituted oxopyridine derivativesInfo
- Publication number
- SG11202104384PA SG11202104384PA SG11202104384PA SG11202104384PA SG11202104384PA SG 11202104384P A SG11202104384P A SG 11202104384PA SG 11202104384P A SG11202104384P A SG 11202104384PA SG 11202104384P A SG11202104384P A SG 11202104384PA SG 11202104384P A SG11202104384P A SG 11202104384PA
- Authority
- SG
- Singapore
- Prior art keywords
- oxopyridine derivatives
- substituted oxopyridine
- substituted
- derivatives
- oxopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122825 | 2018-12-21 | ||
| PCT/EP2019/085983 WO2020127504A1 (en) | 2018-12-21 | 2019-12-18 | Substituted oxopyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104384PA true SG11202104384PA (en) | 2021-05-28 |
Family
ID=69143542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104384PA SG11202104384PA (en) | 2018-12-21 | 2019-12-18 | Substituted oxopyridine derivatives |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3898633A1 (es) |
| JP (1) | JP2022514303A (es) |
| KR (1) | KR20210106504A (es) |
| CN (1) | CN113474348A (es) |
| AR (1) | AR117435A1 (es) |
| AU (1) | AU2019407909B2 (es) |
| BR (1) | BR112021009435A2 (es) |
| CA (1) | CA3124220A1 (es) |
| CL (1) | CL2021001613A1 (es) |
| CO (1) | CO2021007908A2 (es) |
| CR (1) | CR20210342A (es) |
| DO (1) | DOP2021000128A (es) |
| EA (1) | EA202191764A1 (es) |
| EC (1) | ECSP21043895A (es) |
| IL (1) | IL283990A (es) |
| JO (1) | JOP20210161A1 (es) |
| MA (1) | MA54521A (es) |
| MX (1) | MX2021007508A (es) |
| PE (1) | PE20211790A1 (es) |
| SG (1) | SG11202104384PA (es) |
| TW (1) | TW202039510A (es) |
| WO (1) | WO2020127504A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3765452T (pt) * | 2018-03-15 | 2022-06-23 | Bayer Pharma AG | Processo preparativo de dois derivados de 4-{[(2s)-2-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamida |
| CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
| WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| JP2024508970A (ja) | 2021-03-09 | 2024-02-28 | バイエル・アクチエンゲゼルシヤフト | （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含んでいる医薬剤形 |
| CN117015535A (zh) | 2021-03-09 | 2023-11-07 | 拜耳公司 | (4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-5二苯庚烷-74-甲酰胺的结晶形式 |
| CN114560754A (zh) * | 2022-02-25 | 2022-05-31 | 滁州学院 | 一种烷基醇的制备方法 |
| CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| EP2091947A2 (en) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2014160592A2 (en) | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| US9475809B2 (en) | 2013-07-23 | 2016-10-25 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
| US9765070B2 (en) | 2013-10-30 | 2017-09-19 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| WO2016046166A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| EP3197880B1 (de) | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung |
| ES2694189T3 (es) | 2014-09-24 | 2018-12-18 | Bayer Pharma Aktiengesellschaft | Derivados de oxopiridina sustituidos |
| EP3197896B1 (de) | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| WO2016046164A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| US10138236B2 (en) * | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
| EP3271332A1 (de) * | 2015-03-19 | 2018-01-24 | Bayer Pharma Aktiengesellschaft | Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| WO2017037051A1 (de) | 2015-09-04 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
-
2019
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/ar unknown
- 2019-12-18 AR ARP190103745A patent/AR117435A1/es unknown
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en active Active
- 2019-12-18 EA EA202191764A patent/EA202191764A1/ru unknown
- 2019-12-18 TW TW108146372A patent/TW202039510A/zh unknown
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/es unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/pt not_active Application Discontinuation
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/ja active Pending
- 2019-12-18 CR CR20210342A patent/CR20210342A/es unknown
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/es unknown
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/en active Pending
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/zh active Pending
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/en unknown
- 2019-12-18 CA CA3124220A patent/CA3124220A1/en active Pending
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/ko active Search and Examination
- 2019-12-18 MA MA054521A patent/MA54521A/fr unknown
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/es unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/es unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/es unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021007508A (es) | 2021-08-05 |
| IL283990A (en) | 2021-07-29 |
| AU2019407909B2 (en) | 2023-05-25 |
| AR117435A1 (es) | 2021-08-04 |
| CR20210342A (es) | 2021-08-09 |
| PE20211790A1 (es) | 2021-09-09 |
| AU2019407909A1 (en) | 2021-05-27 |
| CN113474348A (zh) | 2021-10-01 |
| TW202039510A (zh) | 2020-11-01 |
| WO2020127504A1 (en) | 2020-06-25 |
| ECSP21043895A (es) | 2021-07-30 |
| BR112021009435A2 (pt) | 2021-08-17 |
| JOP20210161A1 (ar) | 2023-01-30 |
| EP3898633A1 (en) | 2021-10-27 |
| CL2021001613A1 (es) | 2021-12-03 |
| MA54521A (fr) | 2022-03-30 |
| DOP2021000128A (es) | 2021-09-30 |
| CA3124220A1 (en) | 2020-06-25 |
| KR20210106504A (ko) | 2021-08-30 |
| EA202191764A1 (ru) | 2021-10-22 |
| JP2022514303A (ja) | 2022-02-10 |
| CO2021007908A2 (es) | 2021-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3810587T3 (pl) | Podstawione alkoksypirydynyloindolosulfonoamidy | |
| CA185383S (en) | Casque | |
| IL271607B1 (en) | New azaquinoline histories | |
| CA185382S (en) | Casque | |
| CA185385S (en) | Casque | |
| IL283990A (en) | Modified oxopyridine derivatives | |
| IL283197A (en) | Biocidal 2-acylamino-thiazole-4-carboxamide derivatives | |
| ZA202204675B (en) | New methylquinazolinone derivatives | |
| IL289197A (en) | History of 2-hydroxycycloalkane-1-carbamoyl | |
| CA184989S (en) | Uroflowmeter | |
| IL279938A (en) | History of spirochroman | |
| CA184993S (en) | Uroflowmeter | |
| IL290815A (en) | History of alpha-d-galactopyranoside | |
| SI3796975T1 (sl) | Derivati sulfonilaminobenzamida | |
| IL271290A (en) | Dihydro-pyrrolo-pyridine derivatives | |
| PL3770162T3 (pl) | Pochodne dihydrochromenu | |
| SG11202006837XA (en) | Dihydroindolizinone derivative | |
| GB201803155D0 (en) | Spedball | |
| GB201806948D0 (en) | Derivatives | |
| GB201919210D0 (en) | Dihydro-cyclopenta-isoquinoline derivatives | |
| AU201817248S (en) | MC-Roller | |
| AU201817245S (en) | MC-Roller | |
| AU201817247S (en) | MC-Roller | |
| PT3319956T (pt) | Derivados de oxopiridina substituída |